COVID-19 | Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

In the second study in which the protective response was assessed against Omicron variants i.e. BA.1 and BA.2, following three-dose vaccinations, lesser virus shedding, lung viral load, and lung disease severity were observed in the immunised groups in comparison to the placebo groups

June 15, 2022 01:26 pm | Updated June 16, 2022 11:02 pm IST - New Delhi

Covaxin booster immunisation tends to broaden the protective immune response, according to the study. File (representational image)

Covaxin booster immunisation tends to broaden the protective immune response, according to the study. File (representational image) | Photo Credit: Shiv Kumar Pushpakar

The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19’s Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.

The protective efficacy of Bharat Biotech’s Covaxin following two and three-dose immunisations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), it said.

The antibody response, clinical observations, viral load reduction, and lung disease severity after virus challenge were observed, it added.

The findings of the study have been published on June 14 on bioRxiv, a pre-print server and have not been peer reviewed.

“In the Delta infection study, where we compared the protective response between the two and three-dose regimens, we could observe the advantage of the booster dose vaccination in the protection. Although the neutralising antibody levels were comparable among the groups, lung disease severity was found more reduced after the three dose vaccination.

“The virus shedding and viral organ load were considerably reduced in both the two dose and three-dose immunised animals indicating the vaccine efficacy against Delta variant,” the study by Indian Council of Medical Research and Bharat Biotech said.

In the second study in which the protective response was assessed against Omicron variants i.e. BA.1 and BA.2, following three-dose vaccinations, lesser virus shedding, lung viral load, and lung disease severity were observed in the immunised groups in comparison to the placebo groups.

“The evidence from the present study shows that Covaxin booster immunisation tends to broaden the protective immune response and reduces disease severity against the Delta and Omicron variant infection,” it further said.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.